BMS, Exelixis report survival data for RCC therapies

Survival data from Phase III trials of Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) and Cometriq cabozantinib from Exelixis Inc. (NASDAQ:EXEL) to treat advanced or metastatic renal cell carcinoma (RCC) were presented at the European Cancer Congress in Vienna and published in the New England Journal of Medicine.

In July, BMS said its Phase III CheckMate -025 trial of Opdivo met its primary endpoint of improving overall survival (OS) compared to Afinitor everolimus from Novartis AG (NYSE:NVS; SIX:NOVN), and Exelixis reported Cometriq met the primary endpoint of improving progression-free survival (PFS) vs. Afinitor in the Phase III METEOR trial in patients whose disease had progressed after treatment with a VEGF receptor tyrosine kinase inhibitor (TKI) (see BioCentury Extra, July 20). ...